%0 Journal Article
%T The PGC-1/ERR network and its role in precision oncology
%A Ann M. Bode
%A Humberto De Vitto
%A Zigang Dong
%J Archive of "NPJ Precision Oncology".
%D 2019
%R 10.1038/s41698-019-0081-6
%X The PGC-1/ERR network as a potential onco-metabolic target in cancer treatment. a Cancer translational research methodology based on the patient-derived xenograft (PDX) model highlighting drug resistance in cancer. The survival mechanism of residual cells after conventional chemotherapy relies on metabolic plasticity. b The concept of metabolic vulnerability associated with cancer progression can be exploited by targeting a combination of the PGC-1/ERR network and several other mitochondrial weak spots, such as respiratory chain defects, TCA cycle enzymes, including citrate synthase (CS), isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH) and fumarate hydratase (FH). These enzymes might be exploited as potential onco-metabolic targets, depending on the specific type of cance
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428848/